|
|
Search by color, shape and markings. click here
|
|
Check any 2 drugs for interactions. click here
|
|
|
Compare any two drugs side by side. click here
|
|
|
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
|
Calagula, calagualine, ferns, Polypodiaceae (family), Polypodium cambricum, Polypodium decumanum, Polypodium vulgare, samambaia.
Extracts of fern species (family Polypodiaceae) have been used traditionally for numerous indications, most commonly in South America and Europe.
The South American species Polypodium leucotomos L. is commonly known as "calaguala." Extracts of this species, called "anapsos," have been marketed and used as a treatment for multiple indications. Although laboratory and animal studies have reported anti-inflammatory, cytokine-suppressing, and leukotriene inhibitory properties, the small number of available human trials have not demonstrated efficacy for any specific indication.
Atopic dermatitis (eczema):
Laboratory and animal studies report that Polypodium leucotomos extract (anapsos) may reduce inflammation. However, there is little information about the effectiveness of anapsos taken by mouth in people with atopic dermatitis.
Grade: C
Dementia (memory loss, disorientation), Alzheimer's disease:
Limited scientific information is available about the effectiveness of polypodium in the treatment of dementia.
Grade: C
Psoriasis:
Extracts of Polypodium leucotomos (called "anapsos") have been taken by mouth in Europe and South America for psoriasis since the 1970s. Poor-quality human studies report that anapsos may improve skin appearance. However, there is currently little information supporting the use of Polypodium leucotomos for psoriasis. More research is needed in this area before a recommendation can be made.
Grade: C
Skin damage caused by the sun:
Early study shows that polypodium may help to prevent sunburn, skin aging, and skin cancers resulting from uncontrolled overexposure of human skin to solar UV radiation (UVA and UVB). Further research is needed to confirm these results.
Grade: C
Vitiligo (loss of pigment in the skin):
A combination of polypodium and narrow-band UVB (NB-UVB) light therapy may help treat vitiligo, especially on the head and neck. Additional research is needed in this area.
Grade: C
For psoriasis, a dose of 120 milligrams of anapsos (Polypodium leucotomos extract), taken daily by mouth, has been used for short periods of time in limited research. For UV radiation, 7.5 milligrams per kilogram has been studied. For dementia, preliminary research reports using 360 milligrams daily for four weeks. Safety and effectiveness are not clear.
No clear topical (on the skin) dosing regimen has been reported or established.
For vitiligo, 250 milligrams of Polypodium leucotomos has been taken three times daily in combination with narrow-band UVB (NB-UVB) twice weekly for 25-26 weeks.
Little information is available about the use of polypodium in children and safety is not clear.

